6533b82dfe1ef96bd1291580

RESEARCH PRODUCT

Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.

Chiara MediciEliseo AlbertMaura StatzuFabrizio MaggiPietro Giorgio SpeziaDavid NavarroGabriele BiancoCristina CostaDaniele FocosiMauro PistelloCarolina ScagnolariLisa MaceraRossana CavalloGuido Antonelli

subject

0301 basic medicineMaleTime Factorsmedicine.medical_treatmentlcsh:MedicineCytomegalovirusVIROMEPostoperative ComplicationsANELLOVIRUSESlcsh:ScienceKidney transplantationTT VIRUSLUNG TRANSPLANTATIONDNA VIRUSAged 80 and overMultidisciplinaryIMMUNOSUPPRESSIONCMVvirus diseasesImmunosuppressionMiddle AgedViral LoadPrognosissurgical procedures operativeNEXT-GENERATIONCytomegalovirus InfectionsFemaleTORQUE TENO VIRUS; STEM-CELL TRANSPLANTATION; TT VIRUS; LUNG TRANSPLANTATION; NEXT-GENERATION; DNA VIRUS; IMMUNOSUPPRESSION; ANELLOVIRUSES; VIROME; HEPATITISViral loadAdult030106 microbiologyCongenital cytomegalovirus infectionTTVViremiaArticle03 medical and health sciencesHEPATITISYoung AdultmedicineHumansHuman viromeViremiaAgedImmunosuppression TherapyTorque teno virusbusiness.industrylcsh:RTTV; CMV; Transplant patientsSTEM-CELL TRANSPLANTATIONmedicine.diseaseKidney TransplantationTransplant RecipientsTransplantationRegimen030104 developmental biologyImmunologyTransplant patientslcsh:QVirus Activationbusiness

description

AbstractMonitoring the human virome has been recently suggested as a promising and novel area of research for identifying new biomarkers which would help physicians in the management of transplant patients. Imbalance of the immune system in transplant recipients has a significant impact on replication of Torquetenovirus (TTV), the most representative and abundant virus of human virome. TTV kinetic was studied by real-time PCR in 280 liver or kidney transplant recipients who underwent different drug regimens to maintain immunosuppression. During one-year post-transplant follow-up, TTV viremia fluctuated irrespective of transplanted organ type but consistent with the immunosuppression regimen. TTV kinetic in patients who manifested cytomegalovirus (CMV) reactivation within the first four months post-transplant differed from that observed in patients who did not experience CMV complications. Importantly, plasma TTV load measured between day 0 and 10 post-transplant was significantly higher in CMV DNA positive than in CMV DNA negative patients. TTV viremia above 3.45 log DNA copies/ml within the first 10 days post-transplant correlates with higher propensity to CMV reactivation following transplantation. This study provides further evidence for using early post-transplant TTV viremia to predict CMV reactivation in liver or kidney transplant recipients.

10.1038/s41598-018-33909-7https://pubmed.ncbi.nlm.nih.gov/30341363